×
About 59,452 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  27,149 results

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness ...
https://doi.org/10.1182/bloodadvances.2020003541
Blood Advances; Bohl SR, Schmalbrock LK et. al.

May 5th, 2021 - The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma (MM). However, the majority of patients eventually relapse and become resistant to one or multiple drugs. While the genetic landscape of relapse...

MRD Assessment in Multiple Myeloma: Progress and Challenges.
https://doi.org/10.1007/s11899-021-00633-5 10.1038/s41375-019-0660-0
Current Hematologic Malignancy Reports; Bertamini L, D'Agostino M et. al.

May 5th, 2021 - Over the last decade, the development of effective treatment approaches for multiple myeloma (MM) has been associated with higher response rates and longer survival. In patients who achieve complete response, several high sensitivity techniques ha...

Froin Syndrome, a Rare Complication of Multiple Myeloma.
https://doi.org/10.1097/NRL.0000000000000312
The Neurologist; Nizam A, Sivakumar K et. al.

May 4th, 2021 - Froin syndrome is a rare condition that is defined as marked coagulability, elevated protein level, and xanthochromia of the cerebrospinal fluid (CSF). Froin syndrome more commonly occurs because of obstruction of CSF flow due to underlying inflam...

Plasma Cell Proliferation Is Reduced in Myeloma-Induced Hypercalcemia and in Co-Culture...
https://doi.org/10.1093/labmed/lmaa060
Laboratory Medicine; Vazifeh Shiran N, Abroun S

May 4th, 2021 - In multiple myeloma (MM), stimulation of osteoclasts and bone marrow (BM) lesions lead to hypercalcemia, renal failure, and anemia. Co-culture of the myeloma cells in both hypocalcemia and hypercalcemia concentrations with bone marrow-mesenchymal ...

see more →

Guidelines  187 results

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 7th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological mali...
https://doi.org/10.1016/j.kint.2020.07.012
Kidney International; Małyszko J, Bamias A et. al.

Dec 5th, 2020 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute ki...

Mobilization and Exercise Intervention for Patients With Multiple Myeloma: Clinical Pra...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781094
Physical Therapy; Jeevanantham D, Rajendran V et. al.

Sep 25th, 2020 - Individuals with multiple myeloma (MM) often have reduced functional performance due to the cancer itself or as a direct side effect of cancer treatments. Physical therapy is a part of cancer rehabilitation; however, no guidelines are available to...

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or interme...

see more →

Drugs  263 results see all →

Clinicaltrials.gov  29,437 results

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness ...
https://doi.org/10.1182/bloodadvances.2020003541
Blood Advances; Bohl SR, Schmalbrock LK et. al.

May 5th, 2021 - The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma (MM). However, the majority of patients eventually relapse and become resistant to one or multiple drugs. While the genetic landscape of relapse...

MRD Assessment in Multiple Myeloma: Progress and Challenges.
https://doi.org/10.1007/s11899-021-00633-5 10.1038/s41375-019-0660-0
Current Hematologic Malignancy Reports; Bertamini L, D'Agostino M et. al.

May 5th, 2021 - Over the last decade, the development of effective treatment approaches for multiple myeloma (MM) has been associated with higher response rates and longer survival. In patients who achieve complete response, several high sensitivity techniques ha...

Froin Syndrome, a Rare Complication of Multiple Myeloma.
https://doi.org/10.1097/NRL.0000000000000312
The Neurologist; Nizam A, Sivakumar K et. al.

May 4th, 2021 - Froin syndrome is a rare condition that is defined as marked coagulability, elevated protein level, and xanthochromia of the cerebrospinal fluid (CSF). Froin syndrome more commonly occurs because of obstruction of CSF flow due to underlying inflam...

Plasma Cell Proliferation Is Reduced in Myeloma-Induced Hypercalcemia and in Co-Culture...
https://doi.org/10.1093/labmed/lmaa060
Laboratory Medicine; Vazifeh Shiran N, Abroun S

May 4th, 2021 - In multiple myeloma (MM), stimulation of osteoclasts and bone marrow (BM) lesions lead to hypercalcemia, renal failure, and anemia. Co-culture of the myeloma cells in both hypocalcemia and hypercalcemia concentrations with bone marrow-mesenchymal ...

see more →

News  2,379 results

Adding Daratumumab to Triple Therapy Might Help Patients With Newly Diagnosed Multiple Myeloma
https://www.medscape.com/viewarticle/949658

Apr 21st, 2021 - NEW YORK (Reuters Health) - In patients with newly diagnosed multiple myeloma, adding daratumumab to proteasome-inhibitor-based triple therapy is associated with high rates of minimal residual disease (MRD) negativity and excellent progression-fre...

Personalized Cancer Vaccine Shows Early Promise Across Tumor Types
https://www.medscape.com/viewarticle/949339

Apr 14th, 2021 - A personalized genomic cancer vaccine proved feasible to manufacture and was well tolerated in a phase 1 trial, according to researchers. The vaccine, PGV-001, was given to 13 patients with solid tumors or multiple myeloma who had a high risk of r...

Multiple Myeloma Clinical Practice Guidelines (EHA/ESMO, 2021)
https://reference.medscape.com/viewarticle/948408

Mar 31st, 2021 - Clinical guidelines on the management of multiple myeloma (MM) were published in February 2021 by the European Hematology Association and the European Society for Medical Oncology in HemaSphere.[1] Watchful waiting is recommended for patients with...

First CAR T-Cell Therapy for Multiple Myeloma: Abecma
https://www.medscape.com/viewarticle/948248

Mar 28th, 2021 - Chimeric antigen receptor (CAR) T-cell therapy, described as a "living drug," is now available for patients with relapsed/refractory multiple myeloma who have been treated with four or more prior lines of therapy. The US Food and Drug Administrati...

'Phenomenal' Results with CAR T-Cells in R/R Multiple Myeloma
https://www.medscape.com/viewarticle/946733

Mar 1st, 2021 - Patients with multiple myeloma that has continued to progress despite many lines of therapy have shown deep and durable responses to a new chimeric antigen receptor (CAR) T-cell therapy, idecabtagene vicleucel (ide-cel, under development by Bristo...

see more →

Patient Education  37 results see all →